Navigation Links
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
Date:10/31/2007

Small molecule drug inhibits key DNA repair mechanism involved in

resistance

DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced during an oral presentation at the American Society for Therapeutic Radiology and Oncology's (ASTRO) 49th Annual Meeting in Los Angeles that MP470, its clinical-stage multi-targeted tyrosine kinase inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract No. 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented here suggests that MP470 inhibits DNA damage repair through suppression of a critical DNA repair protein, Rad51. Dr. James Welsh of the University of Arizona, who conducted these pre-clinical studies, also revealed that the pre-clinical activity of MP470 against glioblastoma multiforme cells is synergistic with radiation.

Glioblastoma multiforme is often resistant to cytotoxic therapies and radiation, due to increased DNA repair and the inhibition of programmed cell death. Signaling pathways downstream of tyrosine kinases such as PDGFR and c- Met, are thought to be a key player in this resistance. Scientists at SuperGen found that MP470 inhibits these kinases and data presented today indicate that MP470 is active in inducing cell death in glioblastoma multiforme cell lines. Additionally, data suggest that MP470 induces sensitization to radiation through suppression of Rad51, indicating that it might not only inhibit tumor growth, but that it could also potentially enhance current therapies.

A copy of the poster presentation will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.

"There is an urgent need for improved therapies for glioblastoma multiforme," said Dr. Greg Berk, Chief Medical Officer of SuperGen. "Our development strategy in areas of unmet need begins with this type of pre- clinical work that targets the biology of cancer and the weaknesses of current therapies. These studies support further clinical development of MP470 in glioblastoma multiforme."

MP470 is currently being evaluated in a phase 1 single agent clinical trial at two sites and will begin a phase 1b combination clinical trial with multiple chemotherapy regimens later this year.

About Glioblastoma Multiforme

Glioblastoma Multiforme the most common and aggressive malignant brain tumor in adults. Brain tumors are the second leading cause of cancer-related deaths in males ages 20-39 and the fifth leading cause of cancer-related deaths in women ages 20-39. Surgery is generally the first line of treatment, followed by radiation therapy and chemotherapy, either individually or in combination. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastoma multiforme almost always recur and survival rates remain low. Thus the disease remains a significant unmet clinical need in oncology.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Business Manager, Investor

Development Relations

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: tenns@supergen.com E-mail:

mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian American Scientist at Work on Multi-targeted Drug
2. Phase 3 trials of two multi-kinase inhibitors against cancer
3. Enzyme Urokinase Better Option In Empyema For Kids
4. Blood pressure control with ACE inhibitor or diuretic?
5. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
6. Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression
7. Rejuvenation of Stem cells by GSK-3 Inhibitor
8. COX-2 inhibitors Lessen Breast Cancer Risk
9. LipB Protein Inhibitors Help To Fight Against TB
10. Birth Defects Link With ACE Inhibitor Use, FDA Reports
11. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, parent company ... metrics into the product’s app. The data replicates and validates Co-Founder and ... just 30 seconds of using Buzzies, people experienced a 74 percent reduction in ...
(Date:1/23/2017)... ... 2017 , ... PKF O’Connor Davies , LLP, the nation’s 26th largest ... the Firm, will participate in the 40th Annual "Empire State Building Run Up" on ... 1,576 steps, a vertical distance equal to about a fifth of a mile, to ...
(Date:1/23/2017)... ... 2017 , ... Wooden and plastic balance boards have been around since at least the 1950s ... is the first and only balance board to use a patent-pending design featuring high-pressure ... the same time as well as skill-level adjustable for all ages and abilities. The ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... paper on Crystallization in Process Chemistry by Applying Simple PAT Tools . ... organic compounds to isolate and purify the desired product. Chemists now spend ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... GREENWICH, Connecticut , January 24, 2017 ... Gemeinschaftsprojekts mit dem Molecular Surgical Laboratory des Massachusetts General ... angekündigt. Dabei geht es um die Identifizierung und ... von innovativen Ansätzen, dass sie der Resistenz von Antibiotika ... ...
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... , Jan. 23, 2017 INTRODUCTION ... way from conventional syringes with vials to prefilled ... These modern devices have become preferred devices for ... prefilled syringes has been rising strongly over the ... facilities are now adopting this format for delivering ...
Breaking Medicine Technology: